Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL29690831 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3841967 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL29374222 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL14028076 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3885286 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL30244837 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137619 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137618 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102175778-A | Method for synchronously measuring blood drug concentrations of multiple antidepressants | HANGZHOU GUGE SCIENCE AND TECHNOLOGY CO LTD | 2011-09-07 | — | — | CN | claimed |
| CN-101317817-A | External slimming coating agent | ZHONGHUA YUAN (CN) | 2008-12-10 | — | — | CN | claimed |
| CN-101292967-A | Coating agent for preventing and controlling mentation disorder | ZHONGHUA YUAN (CN) | 2008-10-29 | — | — | CN | claimed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3405567-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | Fate Therapeutics, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-3405568-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | Fate Therapeutics, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127729-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017127755-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| CN-102175778-A | Method for synchronously measuring blood drug concentrations of multiple antidepressants | HANGZHOU GUGE SCIENCE AND TECHNOLOGY CO LTD | 2011-09-07 | — | — | CN | disclosed |
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1670427-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1007024-B1 | DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER PROD INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1007024-A1 | DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999001122-A1 | DELAYED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER PRODUCTS INC. (US) | 1999-01-14 | — | — | WO | disclosed |